On Tuesday, Tarsus Pharmaceuticals Inc (NASDAQ: TARS) was 3.96% up from the session before settling in for the closing price of $56.61. A 52-week range for TARS has been $25.53 – $57.90.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -66.60% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 53.53%. With a float of $38.56 million, this company’s outstanding shares have now reached $42.21 million.
Tarsus Pharmaceuticals Inc (TARS) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Tarsus Pharmaceuticals Inc stocks. The insider ownership of Tarsus Pharmaceuticals Inc is 8.65%, while institutional ownership is 107.58%. The most recent insider transaction that took place on Aug 11 ’25, was worth 300,000. In this transaction President/CEO and Board Chair of this company sold 6,000 shares at a rate of $50.00, taking the stock ownership to the 818,106 shares. Before that another transaction happened on Aug 11 ’25, when Company’s Officer proposed sale 6,000 for $50.00, making the entire transaction worth $300,000.
Tarsus Pharmaceuticals Inc (TARS) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.61 earnings per share (EPS) during the time that was better than consensus figure (set at -1) by 0.39. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.03 per share during the current fiscal year.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Trading Performance Indicators
You can see what Tarsus Pharmaceuticals Inc (TARS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.41.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.33, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach 0.97 in one year’s time.
Technical Analysis of Tarsus Pharmaceuticals Inc (TARS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.62 million. That was inferior than the volume of 0.66 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 91.99%.
During the past 100 days, Tarsus Pharmaceuticals Inc’s (TARS) raw stochastic average was set at 99.53%, which indicates a significant increase from 99.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.16 in the past 14 days, which was higher than the 2.07 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $44.50, while its 200-day Moving Average is $47.45. However, in the short run, Tarsus Pharmaceuticals Inc’s stock first resistance to watch stands at $59.85. Second resistance stands at $60.85. The third major resistance level sits at $62.76. If the price goes on to break the first support level at $56.94, it is likely to go to the next support level at $55.04. The third support level lies at $54.04 if the price breaches the second support level.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Key Stats
There are 42,214K outstanding shares of the company, which has a market capitalization of 2.48 billion. As of now, sales total 182,950 K while income totals -115,550 K. Its latest quarter income was 102,660 K while its last quarter net income were -20,340 K.
